Ausgabe 2/2018
Inhalt (11 Artikel)
Leading Article
Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside
Leo F Buckley, Antonio Abbate
Open Access
Review Article
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
Matti Aapro, Andriy Krendyukov, Martin Schiestl, Pere Gascón
Correction
Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
Matti Aapro, Andriy Krendyukov, Martin Schiestl, Pere Gascón
Open Access
Original Research Article
Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis
Edouard Ledent, Hugo Arlegui, Hubert Buyse, Peter Basile, Naveen Karkada, Nicolas Praet, Gaëlle Nachbaur
Original Research Article
Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP®
Yeong Ran Jeong, Rae Ung Jeong, Jeong Hyun Son, Joon Cheol Kwon, Saem Jung, Mi A Song, Jin Ah Hwang, Gyun Min Lee
Original Research Article
Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I
William M. Pardridge, Ruben J. Boado, Roberto Giugliani, Mathias Schmidt
Open Access
Letter to the Editor
Comment on: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
Riccardo Perfetti
Letter to the Editor
Authors’ Reply to Dr. Riccardo Perfetti: “LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes”
Yvette N. Lamb, Yahiya Y. Syed
Correction
Correction to: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
Yvette N. Lamb, Yahiya Y. Syed